OncoSec, 24 North Main Street, Pennington 08534. Daniel O’Connor, CEO. www.oncosec.com.
The biotech company, which is developing immunotherapy-based cancer treatments, has received a $15 million investment from South Korea-based Alpha Holdings.
“This investment from Alpha Holdings is a testament to the growth of OncoSec and the momentum building behind our rapidly advancing TAVO programs, which are designed to enable the intratumoral delivery of IL-12 to stimulate the body’s immune system to target and attack cancer,” said Daniel J. O’Connor, CEO of OncoSec.
“In addition to increasing our current capital, aligning with Alpha Holdings provides an opportunity to strengthen our presence in South Korea and Asia, while developing a long-term relationship with a company that, like OncoSec, recognizes the potential of our TAVO platform to the larger, multi-billion dollar checkpoint market, which has yet to be fully unlocked across multiple cancer types.”
